Analysts Set Progyny, Inc. (NASDAQ:PGNY) Target Price at $25.83

Shares of Progyny, Inc. (NASDAQ:PGNY) have been assigned a consensus rating of “Hold” from the thirteen analysts that are currently covering the stock, Marketbeat reports. Nine analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $25.83.

A number of equities research analysts have recently commented on PGNY shares. Barclays dropped their price objective on shares of Progyny from $30.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Truist Financial restated a “hold” rating and set a $19.00 price target (down previously from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Canaccord Genuity Group decreased their price objective on shares of Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a research report on Wednesday, November 13th. Bank of America increased their target price on shares of Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, February 11th. Finally, JPMorgan Chase & Co. lifted their price target on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th.

Insider Buying and Selling at Progyny

In other news, CEO Peter Anevski acquired 209,500 shares of Progyny stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average cost of $14.48 per share, with a total value of $3,033,560.00. Following the purchase, the chief executive officer now owns 441,463 shares in the company, valued at $6,392,384.24. This trade represents a 90.32 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman David J. Schlanger acquired 150,000 shares of the firm’s stock in a transaction on Thursday, December 26th. The stock was purchased at an average price of $14.68 per share, for a total transaction of $2,202,000.00. Following the acquisition, the chairman now directly owns 228,269 shares in the company, valued at $3,350,988.92. This represents a 191.65 % increase in their position. The disclosure for this purchase can be found here. Insiders own 12.30% of the company’s stock.

Hedge Funds Weigh In On Progyny

Institutional investors and hedge funds have recently bought and sold shares of the business. International Assets Investment Management LLC lifted its stake in Progyny by 1,576.0% in the 3rd quarter. International Assets Investment Management LLC now owns 2,565,118 shares of the company’s stock worth $42,991,000 after purchasing an additional 2,412,068 shares in the last quarter. Louisiana State Employees Retirement System increased its holdings in shares of Progyny by 62.4% in the third quarter. Louisiana State Employees Retirement System now owns 38,000 shares of the company’s stock valued at $637,000 after purchasing an additional 14,600 shares during the last quarter. State of Alaska Department of Revenue lifted its position in Progyny by 397.7% during the third quarter. State of Alaska Department of Revenue now owns 44,819 shares of the company’s stock worth $751,000 after buying an additional 35,813 shares in the last quarter. F M Investments LLC boosted its stake in Progyny by 58.7% during the third quarter. F M Investments LLC now owns 18,078 shares of the company’s stock worth $303,000 after buying an additional 6,684 shares during the last quarter. Finally, AlphaCentric Advisors LLC purchased a new stake in Progyny in the 3rd quarter valued at $126,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Stock Down 0.2 %

Progyny stock opened at $22.98 on Friday. The business’s 50-day moving average price is $20.17 and its 200 day moving average price is $18.62. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of 39.62, a price-to-earnings-growth ratio of 2.39 and a beta of 1.34. Progyny has a 52 week low of $13.39 and a 52 week high of $40.89.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.